The past decade has seen tremendous developments in novel cancer therapies through the
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …

Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast
to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over
the past two decades. Typically DC-based cancer immunotherapy entails loading patient …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via
oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived …

Dendritic cells (DCs) are versatile elements of the immune system and are best known for
their unparalleled ability to initiate and modulate adaptive immune responses. During the …

As the most potent professional antigen presenting cells, dendritic cells (DCs) have the
ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …